SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Tengström, Maria ^a,b,c   Mannermaa, Arto ^a,c   Kosma, Veli Matti ^a,c   Hirvonen, Ari ^d   Kataja, Vesa ^a,b,c  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b VAASA CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ARYL SULFOTRANSFERASE; SULT1A1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SPECIFIC SURVIVAL; CANCER SURVIVAL; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MUTATOR GENE; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; RECURRENCE FREE SURVIVAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SULFOTRANSFERASE 1A1 GENE; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; FINLAND; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ARYLSULFOTRANSFERASE; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FEMALE; FINLAND; GENOTYPE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TAMOXIFEN; YOUNG ADULT;

EID: 84862257238     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-257     Document Type: Article

References (34)

1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ, . Panel members Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20(8):1319-1329. 10.1093/annonc/mdp322, 2720818, 19535820, Panel members.
2. Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378(9793):771-784. 3163848, 21802721, Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998, 351(9114):1451-1467. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
4. Deitcher SR, Gomes MP. The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review. Cancer 2004, 101(3):439-449. 10.1002/cncr.20347, 15274057.
5. Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005, 55(5):471-478. 10.1007/s00280-004-0926-7, 15685451.
6. Nishiyama T, Ogura K, Nakano H, Ohnuma T, Kaku T, Hiratsuka A, Muro K, Watabe T. Reverse geometrical selectivity in glucuronidation and sulfation of cis- and trans-4-hydroxytamoxifens by human liver UDP-glucuronosyltransferases and sulfotransferases. Biochem Pharmacol 2002, 63(10):1817-1830. 10.1016/S0006-2952(02)00994-2, 12034366.
7. Raftogianis RB, Wood TC, Weinshilboum RM. Human phenol sulfotransferases SULT1A2 and SULT1A1: genetic polymorphisms, allozyme properties, and human liver genotype-phenotype correlations. Biochem Pharmacol 1999, 58(4):605-616. 10.1016/S0006-2952(99)00145-8, 10413297.
8. Nowell S, Sweeney C, Winters M, Stone A, Lang NP, Hutchins LF, Kadlubar FF, Ambrosone CB. Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy. J Natl Cancer Inst 2002, 94(21):1635-1640. 10.1093/jnci/94.21.1635, 12419790.
9. Choi JY, Lee KM, Park SK, Noh DY, Ahn SH, Chung HW, Han W, Kim JS, Shin SG, Jang IJ, Yoo KY, Hirvonen A, Kang D. Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14(5):1090-1095. 10.1158/1055-9965.EPI-04-0688, 15894657.
10. Knechtel G, Hofmann G, Gerger A, Renner W, Langsenlehner T, Szkandera J, Wolf G, Samonigg H, Krippl P, Langsenlehner U. Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer. J Cancer Res Clin Oncol 2010, 136(12):1813-1819. 10.1007/s00432-010-0839-2, 20204402.
11. Wegman P, Vainikka L, Stal O, Nordenskjold B, Skoog L, Rutqvist LE, Wingren S. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients. Breast Cancer Res 2005, 7(3):R284-R290. 10.1186/bcr993, 1143572, 15987423.
12. Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, De Lena M, Tancini G, Bajetta E, Musumeci R, Veronesi U. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976, 294(8):405-410. 10.1056/NEJM197602192940801, 1246307.
13. Bonadonna G, Moliterni A, Zambetti M, Daidone MG, Pilotti S, Gianni L, Valagussa P. 30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study. BMJ 2005, 330(7485):217. 10.1136/bmj.38314.622095.8F, 546063, 15649903.
14. De Laurentiis M, Cancello G, D'Agostino D, Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V, Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A, Limite G, Bianco AR, De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 2008, 26(1):44-53. 10.1200/JCO.2007.11.3787, 18165639.
15. Pestalozzi B, Castiglione M, , . ESMO Guidelines Working Group, Primary breast cancer ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008, 19(Suppl 2):ii7-ii10. ESMO Guidelines Working Group, Primary breast cancer.
16. Zhang J, Tian Q, Yung Chan S, Chuen Li S, Zhou S, Duan W, Zhu YZ. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metab Rev 2005, 37(4):611-703. 10.1080/03602530500364023, 16393888.
17. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, Rane A. Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 2003, 3(1):53-61.
18. Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes. Cancer Res 1997, 57(19):4229-4235.
19. Griskevicius L, Yasar U, Sandberg M, Hidestrand M, Eliasson E, Tybring G, Hassan M, Dahl ML. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 2003, 59(2):103-109.
20. Sweeney C, Ambrosone CB, Joseph L, Stone A, Hutchins LF, Kadlubar FF, Coles BF. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment. Int J Cancer 2003, 103(6):810-814. 10.1002/ijc.10896, 12516103.
21. Sweeney C, McClure GY, Fares MY, Stone A, Coles BF, Thompson PA, Korourian S, Hutchins LF, Kadlubar FF, Ambrosone CB. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism. Cancer Res 2000, 60(20):5621-5624.
22. Mitrunen K, Jourenkova N, Kataja V, Eskelinen M, Kosma VM, Benhamou S, Vainio H, Uusitupa M, Hirvonen A. Glutathione S-transferase M1, M3, P1, and T1 genetic polymorphisms and susceptibility to breast cancer. Cancer Epidemiol Biomarkers Prev 2001, 10(3):229-236.
23. Sillanpaa P, Kataja V, Eskelinen M, Kosma VM, Uusitupa M, Vainio H, Mitrunen K, Hirvonen A. Sulfotransferase 1A1 genotype as a potential modifier of breast cancer risk among premenopausal women. Pharmacogenet Genomics 2005, 15(10):749-752. 10.1097/01.fpc.0000172240.34923.46, 16141802.
24. Hartikainen JM, Kataja V, Pirskanen M, Arffman A, Ristonmaa U, Vahteristo P, Ryynanen M, Heinonen S, Kosma VM, Mannermaa A. Screening for BRCA1 and BRCA2 mutations in Eastern Finnish breast/ovarian cancer families. Clin Genet 2007, 72(4):311-320. 10.1111/j.1399-0004.2007.00866.x, 17850627.
25. Engelke CE, Meinl W, Boeing H, Glatt H. Association between functional genetic polymorphisms of human sulfotransferases 1A1 and 1A2. Pharmacogenetics 2000, 10(2):163-169. 10.1097/00008571-200003000-00008, 10762004.
26. Nowell SA, Ahn J, Rae JM, Scheys JO, Trovato A, Sweeney C, MacLeod SL, Kadlubar FF, Ambrosone CB. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients. Breast Cancer Res Treat 2005, 91(3):249-258. 10.1007/s10549-004-7751-x, 15952058.
27. Wegman P, Elingarami S, Carstensen J, Stal O, Nordenskjold B, Wingren S. Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer. Breast Cancer Res 2007, 9(1):R7. 10.1186/bcr1640, 1851378, 17244352.
28. Lien EA, Solheim E, Lea OA, Lundgren S, Kvinnsland S, Ueland PM. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment. Cancer Res 1989, 49(8):2175-2183.
29. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 2006, 8(4):R50. 10.1186/bcr1539, 1779459, 16884532.
30. Sun D, Sharma AK, Dellinger RW, Blevins-Primeau AS, Balliet RM, Chen G, Boyiri T, Amin S, Lazarus P. Glucuronidation of active tamoxifen metabolites by the human UDP glucuronosyltransferases. Drug Metab Dispos 2007, 35(11):2006-2014. 10.1124/dmd.107.017145, 17664247.
31. Dehal SS, Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997, 57(16):3402-3406.
32. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Bolander J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009, 302(13):1429-1436. 10.1001/jama.2009.1420, 19809024.
33. Glatt H. Sulfotransferases in the bioactivation of xenobiotics. Chem Biol Interact 2000, 129(1-2):141-170. 10.1016/S0009-2797(00)00202-7, 11154739.
34. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97(1):30-39. 10.1093/jnci/dji005, 15632378.